Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
2016
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines. The cardiovascular disease (CVD) policy model was used to simulate CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. The authors assumed a willingness-to-pay for health of $50,000/QALY.
Results indicated that treating 0.7 million hypertensive non-Hispanic black adults would prevent about 8,000 CVD events annually; treating 3.4 million non-Hispanic whites would prevent about 35,000 events. Overall, 2014 guideline implementation would be cost saving in both groups compared with no treatment. For stage 1 hypertension but without diabetes or chronic kidney disease, cost savings extended to non-Hispanic black males ages 35-44 but not same-aged non-Hispanic white males (ICER $57,000/QALY) and cost-effectiveness extended to non-Hispanic black females ages 35-44 (ICER $46,000/QALY) but not same-aged non-Hispanic white females (ICER $181,000/QALY).
Based on these findings the authors concluded that compared with non-Hispanic whites, cost-effectiveness of implementing hypertension guidelines would extend to a larger proportion of non-Hispanic black hypertensive patients.
Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
Source:
Vasudeva E, Moise N, Huang C et al. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. American Journal of Hypertension 2016; 29 (10): 1195-1205. https://doi.org/10.1093/ajh/hpw047